US FDA May Largely Avoid House Democrats' Investigation Agenda
Executive Summary
Drug pricing hearings likely will involve FDA, but most pressing issue facing agency following midterms may be whether Commissioner Gottlieb will depart.
You may also be interested in...
Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA
Commissioner Scott Gottlieb will leave FDA less than two years after his confirmation, but will exit with a substantial list of accomplishments for industry and patients.
Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA
Commissioner Scott Gottlieb will leave FDA less than two years after his confirmation, but will exit with a substantial list of accomplishments for industry and patients.
Keeping Up With “The Energizer Bunny”: US FDA Commissioner Gottlieb As A Boss
Three center directors agree that Gottlieb’s facility for public communications is a boon for FDA – and that the commissioner is appropriately hands-off when it comes to day-to-day decisions on scientific or policy issues.